This SOX compliance training will provide a uniquely effective road map to documenting and assessing risks at Pharma/Bio/Life Science companies.
Sarbanes-Oxley Risk Assessment includes COSO, PCAOB Auditing Standard #2 and SEC/PCAOB Q&A’s. Recent PCAOB/SEC Internal Control Roundtables also reiterate the need for management and outside auditors to take a risk based, top down approach toward complying with SOX Section 404.
But what is there secret to effective and affordable compliance? The answer is ’working backwards’! Using database tools and web based technologies participants will learn from historical Section 404 results of peer company internal control and accounting deficiencies.
What is the intent of risk assessment?
Sarbanes-Oxley Risk Assessment includes COSO, PCAOB Auditing Standard #2 and SEC/PCAOB Q&A’s. Recent PCAOB/SEC Internal Control Roundtables also reiterate the need for management and outside auditors to take a risk based, top down approach toward complying with SOX Section 404.
But what is there secret to effective and affordable compliance? The answer is ’working backwards’! Using database tools and web based technologies participants will learn from historical Section 404 results of peer company internal control and accounting deficiencies.
Areas Covered in the seminar:
What is the SOX regulatory environment over risk assessment?What is the intent of risk assessment?
- Focus on materiality
- What advantage to MicroCap companies have?
- What risks have companies in Pharma/Bio/Life Sciences peer groups experienced?
- How do restatements affect risk?
- Sarbanes-Oxley Article’s by Bob Benoit:
- Lord & Benoit Report:404 Bridges the Sarbanes-Oxley Disclosure Control Gap
- Lord & Benoit Report: Do the Benefits of 404 Exceed the Cost?
Who Will Benefit:
- CFOs, Controllers, CIOs, CCOs
- Management
- Audit Committee members
- Consultants
- Software providers
- Outside auditing firms
- Legal professionals
Course Provider
Bob Benoit,
